Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Abstract
Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patients with an expected 5‐year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 12, 2018
- Source ID
- 10.1002/cncr.31374
Entities
People
- Abraham S. Kanate
- Alberto Mussetti
- Alvaro Urbano‐ispizua
- Alyssa Digilio
- Andreas Klein
- Andy Chen
- Anna Sureda
- Asad Bashey
- Ayman Saad
- Bipin N Savani
- David J. Inwards
- Edward Copelan
- Harry C. Schouten
- Hillard M Lazarus
- James Godfrey
- Javier Bolaños‐meade
- Julie Vose
- Kwang Woo Ahn
- Leona Holmberg
- Mahmoud Aljurf
- Mark Hertzberg
- Matthew Mei
- Mehdi Hamadani
- Mitchell S Cairo
- Mohamed A. Kharfan‐dabaja
- Nirav Shah
- Parastoo B. Dahi
- Praveen Ramakrishnan Geethakumari
- Ravi Vij
- Reem Karmali
- Sairah Ahmed
- Saurabh Chhabra
- Siddhartha Ganguly
- Sonali M Smith
- Taiga Nishihori
- Ulrike Bacher
- Umar Farooq
- Vaibhav Agrawal
- Vaishalee P. Kenkre
- Veronika Bachanova
Organizations
- Blue Cross Blue Shield Association
- Case Western Reserve University
- Catalan Institute of Oncology
- Celgene
- Fred Hutchinson Cancer Center
- GSK
- Genzyme
- H. Lee Moffitt Cancer Center & Research Institute
- Health Resources and Services Administration
- Indiana University
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
- Kiadis Pharma (Netherlands)
- King Faisal Specialist Hospital and Research Centre
- Levine Cancer Institute
- Mayo Clinic
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- New York Medical College
- Northwestern University
- Office of Naval Research
- Onyx Pharmaceuticals
- Oregon Health & Science University
- Prince of Wales Hospital, Sydney
- Roswell Park Comprehensive Cancer Center
- Seagen
- Sidney Kimmel Comprehensive Cancer Center
- St. Baldrick's Foundation
- StemCyte
- Tarix Orphan (United States)
- Terumo BCT (United States)
- Thomas Jefferson University
- Tufts Medical Center
- United States Department of Defense
- University of Alabama at Birmingham
- University of Barcelona
- University of Bern
- University of Chicago
- University of Iowa
- University of Kansas
- University of Minnesota
- University of Texas at Austin
- University of Utah
- University of Wisconsin–Madison
- Vanderbilt University
- Washington University in St. Louis
- West Virginia University